CJC + Ipamorelin
Blend combines a GHRH-analogue concept with a ghrelin/GH-secretagogue peptide; published human evidence is mainly on the components separately.
Mechanism & research rationale
CJC-1295 was developed as a long-acting analogue of growth-hormone-releasing hormone (GHRH). Ipamorelin is a growth-hormone secretagogue acting through the ghrelin/GHS receptor pathway. Both can stimulate GH release through different upstream mechanisms, which explains research interest in combined signalling.
Human evidence
A 2006 randomized study of CJC-1295 in healthy adults reported prolonged increases in GH and IGF-1 following the defined investigational analogue. A human PK/PD study of ipamorelin showed a short terminal half-life and a discrete GH-release response. Ipamorelin was also tested in a randomized postoperative-ileus study, where the primary efficacy endpoint was not statistically significant. These studies do not establish efficacy of a retail CJC + ipamorelin blend.
Preclinical / translational evidence
Animal and mechanistic studies explore muscle, endocrine and GH-axis endpoints. Recent reviews describe combination-specific evidence as largely preclinical.
Key limitations
- “CJC” products may differ in analogue/formulation; evidence on one CJC-1295 study compound cannot automatically be generalized.
- Human studies of the two components separately do not validate a fixed-ratio combination.
- Long-term safety and clinically meaningful outcomes for this blend are not established.